HTG Molecular Diagnostics Profit Margin

HTG Molecular Diagnostics (HTGM) currently reports a profit margin of -324.28% as of March 2023. That compares with -216.6% in the prior-year period — down 49.7% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore HTG Molecular Diagnostics's profit margin history and peer comparisons.

HTG Molecular Diagnostics's profit margin decreased from -216.6% to -324.28% — a 49.7% year-over-year decrease (period ending March 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

HTG Molecular Diagnostics's profit margin of -324.28% is lower than the Healthcare sector average of 15.29%. That is roughly 2220.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but HTG Molecular Diagnostics's current -324.28% should be judged against Healthcare norms (sector average: 15.29%) and against HTGM's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -324.28%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for HTG Molecular Diagnostics, and consider following HTGM for alerts when major investors trade the stock.